Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464875 | 0.82 | SLC5A2 (0.42) | ADORA2AADORA2BSLC29A1SLC5A2 | |
| SCHEMBL16138510 | 0.74 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL19807503 | 0.74 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL19464945 | 0.74 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL16310923 | 0.74 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL27730447 | 0.72 | SLC5A2 (0.53) | ADORA2AADORA3ADORA1ADORA2BSLC5A2 | |
| SCHEMBL24983718 | 0.70 | CDA (0.48) | ADORA1SLC29A1TP53MDM2 | |
| SCHEMBL23719101 | 0.68 | SLC5A2 (0.46) | ADORA1SLC5A2MDM2KDM4E | |
| SCHEMBL22933055 | 0.67 | SMN1; SMN2 (0.41) | ADORA1SLC5A2MDM2 | |
| SCHEMBL31685710 | 0.66 | LMNA (0.42) | ADORA1SLC29A1TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135611-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135611-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | ADORA2A 21/4885ADORA3 33/4885ADORA1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.